Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Australia's IVF price wars may lower costs further

29 August 2017

By Shaoni Bhattacharya

Appeared in BioNews 915

Treatment costs for IVF may be coming down in Australia as a result of a price war between fertility clinics.

Two of the country's biggest IVF providers – Virtus Health and the Monash IVF Group – saw lacklustre earnings in financial reports released last week. Competition from low-cost providers and fewer Australians seeking IVF may be to blame, according to media reports.

Fertility services in Australia are overwhelming commercial enterprises - Virtus was the world's first IVF company to float on the stock market in 2013 (see BioNews 709).

Patients accessing fertility services must pay privately (see BioNews 899). They can then claim back for portions of certain costs under the country's Medicare health insurance system, or through private insurance if they have it. But they must be able to afford to pay for costs that are not subsidised by insurance – the so-called 'out-of-pocket' expenses, which may also include certain drugs as well as the remainder of the cost of the main treatments.

Due to competition, Virtus has now adjusted treatment prices at its cheaper clinic chain, The Fertility Centre, to between AU $900 and AU $1500 out-of-pocket costs, Sue Channon, group chief executive officer of Virtus, said according to newspaper the Sydney Morning Herald.

The equivalent costs at a clinic run by low-cost provider Primary Health Care are AUS $800. This provider launched in 2014, with the aim of offering low-cost IVF by bulk-billing all the associated costs covered by Medicare. According to Primary IVF's website: 'The only out of pocket expenses you will incur are those not covered by Medicare, however, these may not be applicable to all patients.'

Professor Alan Trounson at Monash University suggested prices could fall further. 'I do think the price could go lower,' he said, reported the newspaper. 'At least for younger patients, where the woman is under 38 years of age and the men are in their late 40s, their fertility is pretty strong and I think they could be treated in a much more economical manner than they are currently being treated.'

But demand for IVF in the country has also fallen. According to the Sydney Morning Herald the number of total IVF cycles in Australia were down by 1.2 percent in the year to June.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

03 November 2017 - by Georgia Everett 
Australian bioethicists have expressed concern that the country's assisted reproductive technology (ART) industry has become increasingly motivated by profit, causing a conflict of interest...
11 September 2017 - by Professor Alan Trounson and Dr Karin Hammarberg 
In Australia, almost four percent of children are born as a result of assisted reproductive technologies. The comparatively high rate of ART use is in part due to costs being covered by the taxpayer-funded health insurance scheme, Medicare...

08 May 2017 - by Dr Jane Williams 
Australia's key body for medical research released a new set of ethical guidelines last month on the use of Assisted Reproduction Technologies with a welcome and unusual surprise: a section on conflicts of interest...
08 August 2016 - by Antony Blackburn-Starza 
Fertility clinics in Australia have been warned not to offer flat fees to egg and sperm donors, reports the Sydney Morning Herald...
06 June 2016 - by Dr Mary Yarwood 
An Australian documentary has claimed that women over 40 are being misled about their chances of conceiving via IVF treatment when using their own eggs...
30 June 2014 - by Ayesha Ahmad 
An Australian fertility company has seen the price of its shares rise on the first day of its public listing on the stock market....
17 June 2013 - by Jessica Ware 
The first IVF business to be listed on the stock market enjoyed a buoyant first day of trading on the Australian exchange. Shares in Virtus Health closed 8.5 percent above their starting price, which was already set at the top end of an indicative range...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation